Aim: The aim of this study is to describe the clinical and pathologic features of corneal primary acquired melanosis (PAM) and melanoma. Methods: We describe 3 cases in total: two cases of corneal melanomas and 1 case of corneal PAM. The eyes were processed routinely for histopathological examination. Clinical histories, treatments, and outcomes were reviewed. Results: Corneal melanomas arose from recurrence of conjunctival melanoma or conjunctival PAM at the limbus. One patient had a recurrence after excision of a limbal melanoma, another had a de novo corneal melanoma, and the last patient had corneal PAM in the setting of conjunctival PAM with atypia. All lesions were excised with adjuvant alcohol debridement and cryotherapy with no recurrence ranging from 1 week to 8 years. Conclusions: Corneal melanomas arise at the limbus from corneal PAM or conjunctival atypia. They can appear after excisional removal of a conjunctival melanoma. Surgical excision with alcohol debridement and adjuvant cryotherapy is successful.

1.
Wong
JR
,
Nanjp
AA
,
Galor
A
,
Karp
CL
.
Management of ocnjunctival malignant melanoma: a review and update
.
Expert Rev Ophthalmol
.
2015
;
9
(
3
):
185
204
.
2.
Shields
CL
,
Shields
JA
.
Tumors of the conjunctiva and cornea
.
Surv Ophthalmol
.
2004
;
49
(
1
):
3
24
. .
3.
Tuomaala
S
,
Aine
E
,
Saari
KM
,
Kivelä
T
.
Corneally displaced malignant conjunctival melanomas
.
Ophthalmology
.
2002
;
109
(
5
):
914
9
. .
4.
Reese
A
.
Tumors of the eye
. 2nd ed.
Hoeber
;
1963
.
5.
Uçakhan-Gündüz
Ö
,
Gündüz
K
,
Karsloğlu
MZ
,
Okçu-Heper
A
,
Kanpolat
A
.
Corneal melanoma: report of three cases
.
Eye Contact Lens
.
2012
;
38
(
5
):
341
4
. .
6.
Romaniuk
W
,
Koziol
H
,
Muskalski
K
,
Dorecka
M
,
Tarnawska
D
,
Sabat
D
.
A unique case of primary corneal melanoma
.
Jpn J Ophthalmol
.
2002
;
46
(
1
):
114
6
. .
7.
Davies
WS
,
Bailey
WH
.
Malignant melanoma of the cornea; report of a case
.
AMA Arch Ophthalmol
.
1954
;
52
(
6
):
923
4
. .
8.
Paridaens
ADA
,
Kirkness
CM
,
Garner
A
,
Hungerford
JL
.
Recurrent malignant melanoma of the corneal stroma: a case of “black cornea”
.
Br J Ophthalmol
.
1992
;
76
(
7
):
444
6
.
9.
Schofield
PB
.
Non-pigmented intra-epithelial melanoma of cornea
.
Br J Ophthalmol
.
1958
;
42
(
2
):
99
105
. .
10.
Panagiotou
DZ
,
Chranioti
AA
,
Tzorakoleftheraki
SE
,
Ziakas
NG
,
Oikonomidis
PK
.
Primary melanoma of the cornea
.
GMS Ophthalmol Cases
.
2020
;
10
:
Doc12
5
. .
11.
Naseri
A
,
Char
DH
,
Howes
E
,
Paglen
P
.
Amelanotic corneal melanoma after a blast injury
.
Am J Ophthalmol
.
2001
;
131
(
2
):
259
60
. .
12.
Shields
CL
,
Shields
JA
,
Gündüz
K
,
Cater
J
,
Mercado
GV
,
Gross
N
, et al.
Conjunctival melanoma: risk factors for recurrence, exenteration, metastasis, and death in 150 consecutive patients
.
Arch Ophthalmol
.
2000
;
118
(
11
):
1497
507
.
13.
Henkind
P
.
Migration of limbal melanocytes
.
Nature
.
1967
;
214
(
5095
):
1349
51
. .
14.
Smolin
G
,
Thoft
R
.
The cornea: scientific foundations and clinical practice
. 2nd ed.;
1987
.
15.
Utman
SA
,
James
JN
,
Ramsden
KL
,
Baig
HM
.
Invasive malignant melanoma of the cornea after industrial injury
.
Int Ophthalmol
.
2014
;
34
(
2
):
289
91
. .
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.